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Background
Endocrine therapy is an effective treatment of estrogen
receptor-positive (ER+) breast tumors, significantly redu-
cing mortality. However, approximately 30% of patients
receiving adjuvant endocrine therapy will experience
recurrence within a 15-year period. The mechanisms of
endocrine resistance are poorly understood. Understand-
ing the underlying genetic diversity of breast cancers
responding differently to endocrine therapy is important
for the development of more optimal and individualized
treatments strategies.
Materials and methods
In the current study, a panel of isogenic MCF-7-derived
human breast cancer cell lines [1-3] that are resistant to
tamoxifen only, or to both tamoxifen and fulvestrant,
respectively, were analyzed for mutations through exome
sequencing and compared with the exome of the parental
cell line. In addition, global gene expression levels for the
same panel of cell lines were generated. Detected varia-
tions were integrated with gene expression profiles and
analyzed in the context of prior knowledge of drug action
and genes associated with resistance to endocrine thera-
pies as identified by extensive literature curation.
Results and conclusion
A small panel of somatic point mutations potentially asso-
ciated with acquired endocrine resistance were identified.
Future experimental validation will reveal which of the
detected mutations that are causatively involved in resis-
tance to endocrine therapy.
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